CreativeOne Wealth LLC Acquires 2,023 Shares of Zoetis Inc. (NYSE:ZTS)

CreativeOne Wealth LLC lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 16.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,408 shares of the company’s stock after purchasing an additional 2,023 shares during the period. CreativeOne Wealth LLC’s holdings in Zoetis were worth $2,815,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Cetera Investment Advisers increased its holdings in Zoetis by 275.2% in the 1st quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock worth $16,259,000 after acquiring an additional 70,476 shares during the last quarter. Simplify Asset Management Inc. purchased a new stake in Zoetis in the 3rd quarter worth about $11,684,000. Soltis Investment Advisors LLC purchased a new stake in Zoetis in the 1st quarter worth about $688,000. Bank Pictet & Cie Asia Ltd. increased its holdings in Zoetis by 41.0% in the 2nd quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock worth $6,501,000 after acquiring an additional 10,900 shares during the last quarter. Finally, Swedbank AB increased its holdings in Zoetis by 56.2% in the 2nd quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock worth $337,407,000 after acquiring an additional 700,398 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ZTS has been the subject of several recent research reports. Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Price Performance

ZTS opened at $176.74 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The stock has a market capitalization of $79.74 billion, a PE ratio of 33.22, a price-to-earnings-growth ratio of 2.70 and a beta of 0.90. The stock’s 50 day moving average price is $184.51 and its 200-day moving average price is $180.81.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.36 earnings per share. On average, equities research analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis’s payout ratio is 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.